Safety precautions and suggestions that patients should pay attention to while taking imatinib (Gleevec)

Imatinib (Imatinib) is a targeted drug targeting the BCR-ABL fusion gene. It is mainly used for the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST). During medication, patients need to pay attention to various safety matters to ensure the efficacy of the medication while reducing the risk of adverse reactions.

During the period of taking the medicine, patients should strictly follow the doctor's instructions and take it on time and in the right amount, and should not adjust the dosage or stop the medicine at will. It is generally recommended to take imatinib once a day with food or on an empty stomach. Do not change the taking time or miss taking the medicine. If a dose is missed, it should be taken as soon as possible after discovery. However, if the next dose is close to the time, the current dose should be skipped to avoid toxic side effects caused by a one-time overdose.

Patients should undergo regular blood routine, liver and kidney function and electrocardiogram monitoring. Imatinib may cause a decrease in platelets, white blood cells, or hemoglobin, and may also affect liver function or heart electrical activity. Early detection of abnormal indicators can help doctors adjust dosage or provide supportive treatment in a timely manner to prevent serious complications. In addition, if severe edema, diarrhea, rash or persistent fever occurs, you should seek medical treatment in time and do not use self-medication to relieve it.

Patients need to pay attention to lifestyle and daily care. Avoid overexertion, maintain a balanced diet, drink enough fluids, and avoid taking drugs with which imatinib may interact, such as certain antifungals or strong acid-suppressing drugs. Avoid consuming large amounts of grapefruit or foods containing grapefruit ingredients during medication to avoid affecting drug metabolism. Maintaining good personal hygiene and preventing infections is especially important for patients with low immunity.

Patients should establish a good communication mechanism and promptly report changes in physical condition and potential adverse reactions to the attending physician. Family members or caregivers can help record medication time, symptom changes, and laboratory test results to provide a reference for doctors to adjust treatment plans. Through standardized medication, regular monitoring, scientific life intervention and timely communication, the efficacy and safety of imatinib can be ensured to the greatest extent and the quality of life of patients can be improved.

Reference materials:https://www.drugs.com/